Art

J-GLOBAL ID：202002277737638106   Reference number：20A0500827

Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets

多発性骨髄腫におけるモノクローナル抗体療法:新規標的開発への挑戦【JST・京大機械翻訳】

Author (3)： Nishida Hiroko ( Department of Pathology, Keio University, School of Medicine, Tokyo 160-8582, Japan) ,  Yamada Taketo ( Department of Pathology, Keio University, School of Medicine, Tokyo 160-8582, Japan) ,  Yamada Taketo ( Department of Pathology, Saitama Medical University, Faculty of Medicine, Saitama 350-0495, Japan)
Material： Journal of Oncology (Web)
Volume： 2019  Page： Null  Publication year： 2019 
JST Material Number： U7781A  ISSN： 1687-8450  Document type： Article
Article type： 文献レビュー  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： The treatment options in multi...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A0500827&from=J-GLOBAL&jstjournalNo=U7781A") }}

Thesaurus term： *monoclonal antibody ,  effectiveness ,  *multiple myeloma ,  immunotherapy ,  *antibody ,  complex(substance) ,  drug therapy ,  multiplex ,  immunotherapeutic drug ,  wrench ,  T cell ,  aromatic carboxylic acid ,  acid imide ,  polynuclear aromatic compound ,  dicarboxylic acid
Semi thesaurus term： 血液癌 ,  ヒストンデアセチラーゼ阻害剤 ,  プロテアソーム阻害剤 ,  *ミエローマ , 【Automatic Indexing@JST】

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Blood cell tumors(=neoplasms)  (GK04000M)

Substance index (1)： Thalidomide

Reference (100)：

• A. Palumbo, K. Anderson, "Multiple myeloma," New England Journal of Medicine, vol. 364, no. 11, pp. 1046-1060, 2011.
• P. Moreau, E. de Wit, "Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions," British Journal of Haematology, vol. 179, no. 2, pp. 198-218, 2017.
• C. Varga, J. P. Laubach, K. C. Anderson, P. G. Richardson, "Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma," British Journal of Haematology, vol. 181, no. 4, pp. 433-446, 2018.
• H. Avet-Loiseau, R. Fonseca, D. Siegel et al., "Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma," Blood, vol. 128, no. 9, pp. 1174-1180, 2016.
• A. K. Stewart, S. V. Rajkumar, M. A. Dimopoulos et al., "Carfilzomib, lenalidomide and dexamethasone for relapsed multiple myeloma," New England Journal of Medicine, vol. 372, no. 2, pp. 142-152, 2015.

Terms in the title (5)： 多発性骨髄腫 ,  モノクローナル抗体 ,  療法 ,  標的 ,  開発